Insciences organisation
Published on 25 February 2010, 03:39
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal...
While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey (CINJ) are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients. CINJ is a Center...
ZURICH (Reuters) - Roche Holding's cancer drug Avastin missed its main target in a late-stage trial when used with chemotherapy to treat patients with advanced stomach cancer, the Swiss drugmaker said on Tuesday.
Roche had indicated peak sales of the drug for the disease could have hit between 500 million and 1 billion Swiss francs ($466-$933 million), according to Deutsche Bank analysts.
Clarient Insight(R) Dx Pulmotype(R) Test Aids Physicians in Classifying Subtypes of Lung Cancer, Identifying Most Effective Therapy
ALISO VIEJO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer...
ZURICH (Reuters) - Roche Holding AG said on Wednesday three studies on its drugs used to treat early and advanced breast cancer showed good results.
The Swiss drugmaker, the world's largest maker of cancer drugs, was due to present the results in coming days at the San Antonio Breast Cancer Symposium.
Roche said it would present five-year follow-up data from two studies into the use of Herceptin in early breast cancer...
